Researcher: Bülbül, Mustafa Cem
Loading...
Name Variants
Bülbül, Mustafa Cem
Email Address
Birth Date
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease(Springer, 2021) Afsar, Baris; Sag, Alan A.; Siriopol, Dimitrie; Kuwabara, Masanari; Badarau, Silvia; Covic, Adrian; Ortiz, Alberto; N/A; Kanbay, Mehmet; Çöpür, Sidar; Bülbül, Mustafa Cem; Faculty Member; Researcher; Researcher; School of Medicine; School of Medicine; School of Medicine; 110580; 368625; 327626The most common cause of liver disease worldwide is now non-alcoholic fatty liver disease (NAFLD). NAFLD refers to a spectrum of disease ranging from steatosis to non-alcoholic steatohepatitis, causing cirrhosis, and ultimately hepatocellular carcinoma. However, the impact of NAFLD is not limited to the liver. NAFLD has extra-hepatic consequences, most notably, cardiovascular and renal disease. NAFLD and chronic kidney disease share pathogenic mechanisms including insulin resistance, lipotoxicity, inflammation and oxidative stress. Not surprisingly, there has been a recent surge in efforts to manage NAFLD in an integrated way that not only protects the liver but also delays comorbidities such as chronic kidney disease. This concept of simultaneously addressing the main disease target and comorbidities is key to improve outcomes, as recently demonstrated by clinical trials of SGLT2 inhibitors and GLP1 receptor agonists in diabetes. HIF activators, already marketed in China, also have the potential to protect both liver and kidney, as suggested by preclinical data. This review concisely discusses efforts at identifying common pathogenic pathways between NAFLD and chronic kidney disease with an emphasis on potential paradigm shifts in diagnostic workup and therapeutic management.Publication Metadata only A 70-year-old patient with seronegative lupus nephritis: rare case(Logos Tıp Yayıncılığı, 2018) N/A; N/A; N/A; N/A; N/A; N/A; Dağel, Tuncay; Meram, Ece; Önal, Emine Meltem; Erbil, Damla; Bülbül, Mustafa Cem; Uysal, Sanem Pınar; Doctor; Undergraduate Student; Undergraduate Student; Undergraduate Student; Researcher; Undergraduate Student; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; 327626; N/ASystemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with various kinds of autoantibodies such as Antinuclear antibodies (ANA). ANA is found to be positive in most of the SLE patients. In fact, ANA positivity in serum is one of the diagnostic criteria of SLE. However, a minority of SLE patients may present with ANA negativity. We report a 70-year-old female who presented with massive edema and 10-gram/day proteinuria. Her serum antibodies for SLE were all negative and the renal biopsy showed a class V lupus nephritis. This case was unusual type of SLE due to multiple reasons namely the patient was an elderly woman, with isolated lupus nephritis and negative serology including ANA negativity.Publication Metadata only Iron in kidney and heart failure: from theory to practice(Springer, 2018) Afsar, Baris; Voroneanu, Luminita; Siriopol, Dimitire; Covic, Adrian; N/A; N/A; N/A; N/A; N/A; Yerlikaya, Aslıhan; Bülbül, Mustafa Cem; Dağel, Tuncay; Aslan, Gamze; Kanbay, Mehmet; Undergraduate Student; Researcher; Doctor; Doctor; Faculty Member; School of Medicine; School of Medicine; N/A; N/A; School of Medicine; N/A; N/A; Koç University Hospital; School of Medicine; N/A; N/A; 327626; N/A; N/A; 110580There is evidence that serum iron levels, regardless of the presence of anemia, directly impact outcomes in congestive heart failure (CHF) including quality of life, hospitalization rate and overall survival. Despite modern medical treatments, the prognosis of CHF remains grim. Ironically, simple iron replenishment may serve as a powerful tool in the armamentarium. This review will start from fundamental concepts of iron in oxygen delivery and analyze evidence-based outcomes in CHF iron-directed therapeutic trials. Imaging rationale that dovetails with this pathophysiology will also be detailed in a clinician-directed fashion.Publication Metadata only Disorders of lipid metabolism in chronic kidney disease(Karger Publishers, 2018) Afsar, Baris; Kuwabara, Masanarini; Covic, Adrian; N/A; Kanbay, Mehmet; Bülbül, Mustafa Cem; Dağel, Tuncay; Ulusu, Nuriye Nuray; Faculty Member; Researcher; Doctor; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; N/A; N/A; Koç University Hospital; N/A; 110580; 327626; N/A; 6807Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD). One of the most important pathophysiological mechanisms for CVD in patients with CKD is the widespread and possibly accelerated formation of atherosclerotic plaques due to hyperlipidemia, uremic toxins, inflammation, oxidative stress, and endothelial dysfunction. Recent studies showed that the level of oxidized lowdensity lipoprotein cholesterol increases, and that high-density lipoprotein cholesterol dysfunction occurs as kidney function declines and inflammation becomes more prevalent. In this review, we aimed to discuss the effect of kidney dysfunction, oxidative stress, and inflammation on lipid profile.Publication Metadata only Polycystic kidney disease (PKD) of early childhood due to PKD1/TSC2 contiguous gene deletion syndrome, PKD with tuberous sclerosis complex(Springer, 2018) N/A; N/A; N/A; N/A; Bülbül, Mustafa Cem; Taşdemir, Mehmet; Eraslan, Serpil; Ocak, Seda; Kayserili, Hülya; Bilge, İlmay; Researcher; Faculty Member; Researcher; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 175867; N/A; N/A; 7945; 198907N/A